Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 5 (May)

1. Charge-directed targeting of antimicrobial protein-nanoparticle conjugates.
   Biotechnol Bioeng, 100(3): 403-12. [Abstract] [Full-text]
2. Microfluidic electroporation for delivery of small molecules and genes into cells using a common DC power supply.
   Biotechnol Bioeng, 100(3): 579-86. [Abstract] [Full-text]
3. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
   Lancet Oncol, 9(5): 435-44. [Abstract] [Full-text]
4. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
   Cancer Res, 68(9): 3516-22. [Abstract] [Full-text]
5. TRAIL inactivates the mitotic checkpoint and potentiates death induced by microtubule-targeting agents in human cancer cells.
   Cancer Res, 68(9): 3440-9. [Abstract] [Full-text]
6. Sequential transcription factor targeting for diffuse large B-cell lymphomas.
   Cancer Res, 68(9): 3361-9. [Abstract] [Full-text]
7. Needle-free powder lidocaine delivery system provides rapid effective analgesia for venipuncture or cannulation pain in children: randomized, double-blind Comparison of Venipuncture and Venous Cannulation Pain After Fast-Onset Needle-Free Powder Lidocaine or Placebo Treatment trial.
   Pediatrics, 121(5): 979-87. [Abstract] [Full-text]
8. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
   Pediatrics, 121(5): e1229-39. [Abstract] [Full-text]
9. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
   Pediatrics, 121(5): e1201-7. [Abstract] [Full-text]
10. Adolescent use of insulin and patient-controlled analgesia pump technology: a 10-year Food and Drug Administration retrospective study of adverse events.
    Pediatrics, 121(5): e1133-8. [Abstract] [Full-text]
11. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study.
    Pediatrics, 121(5): e1310-8. [Abstract] [Full-text]
12. 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual.
    Am J Psychiatry, 165(5): 631-8. [Abstract] [Full-text]
13. Quality of pharmacotherapy and outcomes for older veterans discharged from the emergency department.
    J Am Geriatr Soc, 56(5): 875-80. [Abstract] [Full-text]
14. Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma.
    Gynecol Oncol, 109(2): 291-5. [Abstract] [Full-text]
15. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
    J Thorac Cardiovasc Surg, 135(5): 1036-41. [Abstract] [Full-text]
16. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.
    BJU Int, 101(11): 1356-61. [Abstract] [Full-text]
17. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
    Br J Cancer, 98(9): 1500-7. [Abstract] [Full-text]
18. Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
    Cancer, 112(10): 2181-7. [Abstract] [Full-text]
19. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
    BJU Int, 101(11): 1347-55. [Abstract] [Full-text]
20. Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice.
    Cancer, 112(10): 2159-65. [Abstract] [Full-text]
21. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy.
    Cancer, 112(10): 2228-32. [Abstract] [Full-text]
22. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.
    Cancer, 112(10): 2267-73. [Abstract] [Full-text]
23. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
    Gynecol Oncol, 109(2): 174-81. [Abstract] [Full-text]
24. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Gynecol Oncol, 109(2): 250-4. [Abstract] [Full-text]
25. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
    Urology, 71(5): 942-6. [Abstract] [Full-text]
26. Postsurgical administration of estradiol benzoate decreases tensile strength of healing skin wounds in ovariectomized rats.
    J Surg Res, 147(1): 117-22. [Abstract] [Full-text]
27. Adverse events associated with prolonged antibiotic use.
    Pharmacoepidemiol Drug Saf, 17(5): 523-32. [Abstract] [Full-text]
28. Patterns, effects, and thoracic volume changes of thoracoscopic pleurodesis in rabbits.
    J Surg Res, 147(1): 34-40. [Abstract] [Full-text]
29. Enhanced anti-tumor effects achieved in a murine tumor model using combination therapy of recombinant human manganese superoxide dismutase and adriamycin.
    Biochem Biophys Res Commun, 370(4): 663-8. [Abstract] [Full-text]
30. Pyrrhocoricin as a potential drug delivery vehicle for Cryptosporidium parvum.
    Exp Parasitol, 119(2): 301-3. [Abstract] [Full-text]
31. Factors affecting toxicity and efficacy of polymeric nanomedicines.
    Toxicol Appl Pharmacol, 229(1): 121-34. [Abstract] [Full-text]
32. Preparing polymer-based sustained-release systems without exposing proteins to water-oil or water-air interfaces and cross-linking reagents.
    J Control Release, 128(1): 50-9. [Abstract] [Full-text]
33. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles.
    J Control Release, 128(1): 60-70. [Abstract] [Full-text]
34. Functionalized micelles from block copolymer of polyphosphoester and poly(varepsilon-caprolactone) for receptor-mediated drug delivery.
    J Control Release, 128(1): 32-40. [Abstract] [Full-text]
35. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.
    J Control Release, 128(1): 23-31. [Abstract] [Full-text]
36. Dexamethasone acetate encapsulation into Trojan particles.
    J Control Release, 128(1): 41-9. [Abstract] [Full-text]
37. The potential of lipid- and polymer-based drug delivery carriers for eradicating biofilm consortia on device-related nosocomial infections.
    J Control Release, 128(1): 2-22. [Abstract] [Full-text]
38. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
    J Natl Cancer Inst, 100(9): 672-9. [Abstract] [Full-text]
39. Comparison of two methods for performing treatment reviews by pharmacists and general practitioners for home-dwelling elderly people.
    J Eval Clin Pract, 14(3): 446-52. [Abstract] [Full-text]
40. Influence exerted on drug prescribing by patients' attitudes and expectations and by doctors' perception of such expectations: a cohort and nested case-control study.
    J Eval Clin Pract, 14(3): 453-9. [Abstract] [Full-text]
41. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    J Clin Oncol, 26(14): 2390-3295. [Abstract] [Full-text]
42. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.
    J Clin Oncol, 26(14): 2384-9. [Abstract] [Full-text]
43. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma.
    J Clin Oncol, 26(14): 2379-83. [Abstract] [Full-text]
44. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.
    J Clin Oncol, 26(14): 2342-9. [Abstract] [Full-text]
45. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.
    J Clin Oncol, 26(14): 2320-6. [Abstract] [Full-text]
46. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
    J Clin Oncol, 26(14): 2292-8. [Abstract] [Full-text]
47. Is personalized medicine finally arriving?
    Nat Biotechnol, 26(5): 509-17. [Abstract] [Full-text]
48. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.
    Nat Biotechnol, 26(5): 561-9. [Abstract] [Full-text]
49. Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus.
    Nat Biotechnol, 26(5): 571-7. [Abstract] [Full-text]
50. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
    J Clin Oncol, 26(14): 2258-63. [Abstract] [Full-text]
51. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    J Clin Oncol, 26(14): 2311-9. [Abstract] [Full-text]
52. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
    J Clin Oncol, 26(14): 2364-72. [Abstract] [Full-text]
53. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
    Am J Epidemiol, 167(10): 1207-16. [Abstract] [Full-text]
54. Hemorrhagic shock and resuscitation-mediated tissue water distribution is normalized by adjunctive peritoneal resuscitation.
    J Am Coll Surg, 206(5): 970-80; discussion 980-3. [Abstract] [Full-text]
55. Association of timely administration of prophylactic antibiotics for major surgical procedures and surgical site infection.
    J Am Coll Surg, 206(5): 814-9; discussion 819-21. [Abstract] [Full-text]
56. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent.
    J Biomed Mater Res A, 85(4): 1064-71. [Abstract] [Full-text]
57. In situ SAXRD study of sol-gel induced well-ordered mesoporous bioglasses for drug delivery.
    J Biomed Mater Res A, 85(4): 1032-42. [Abstract] [Full-text]
58. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
    Br J Cancer, 98(10): 1614-8. [Abstract] [Full-text]
59. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
    Br J Cancer, 98(10): 1619-29. [Abstract] [Full-text]
60. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
    Br J Cancer, 98(10): 1710-5. [Abstract] [Full-text]
61. Improvement in the suspension-culture production of recombinant adeno-associated virus-LacZ in HEK-293 cells using polyethyleneimine-DNA complexes in combination with hypothermic treatment.
    Biotechnol Appl Biochem, 50: 121-32. [Abstract] [Full-text]
62. Beyond abuse and exposure: framing the impact of prescription-medication sharing.
    Am J Public Health, 98(6): 1115-21. [Abstract] [Full-text]
63. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy.
    Int J Radiat Oncol Biol Phys, 71(2): 611-7. [Abstract] [Full-text]
64. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy.
    J Viral Hepat, 15(6): 427-33. [Abstract] [Full-text]
65. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease.
    Am J Gastroenterol, 103(5): 1193-6. [Abstract] [Full-text]
66. A preoperative decolonization protocol for staphylococcus aureus prevents orthopaedic infections.
    Clin Orthop Relat Res, 466(6): 1343-8. [Abstract] [Full-text]
67. Staphylococcus aureus nasal decolonization in joint replacement surgery reduces infection.
    Clin Orthop Relat Res, 466(6): 1349-55. [Abstract] [Full-text]
68. Gastrointestinal complications of HIV infection: changing priorities in the HAART era.
    Gut, 57(6): 861-70. [Abstract] [Full-text]
69. Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells.
    Oncogene, 27(22): 3134-44. [Abstract] [Full-text]
70. 3D Multi-agent models for protein release from PLGA spherical particles with complex inner morphologies.
    Theory Biosci, 127(2): 95-105. [Abstract] [Full-text]
71. Disposition of valganciclovir during continuous renal replacement therapy in two lung transplant recipients.
    J Antimicrob Chemother, 61(6): 1332-5. [Abstract] [Full-text]
72. Premedication with pregabalin 75 or 150 mg with ibuprofen to control pain after day-case gynaecological laparoscopic surgery.
    Br J Anaesth, 100(6): 834-40. [Abstract] [Full-text]
73. Head and neck cancer.
    Lancet, 371(9625): 1695-709. [Abstract] [Full-text]
74. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
    Lancet, 371(9625): 1685-94. [Abstract] [Full-text]
75. Hydroxycamptothecin-loaded nanoparticles enhance target drug delivery and anticancer effect.
    BMC Biotechnol, 8: 46. [Abstract] [Full-text]
76. Clinical impact of false-negative sentinel lymph nodes in breast cancer.
    Eur J Surg Oncol, 34(6): 620-5. [Abstract] [Full-text]
77. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
    J Clin Oncol, 26(15): 2526-31. [Abstract] [Full-text]
78. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    J Clin Oncol, 26(15): 2489-96. [Abstract] [Full-text]
79. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
    J Clin Oncol, 26(15): 2457-63. [Abstract] [Full-text]
80. Dispensing of anxiolytics and hypnotics in southeastern France: demographic factors and determinants of geographic variations.
    Fundam Clin Pharmacol, 22(3): 323-33. [Abstract] [Full-text]
81. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
    J Clin Oncol, 26(15): 2550-7. [Abstract] [Full-text]
82. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
    J Clin Oncol, 26(15): 2512-8. [Abstract] [Full-text]
83. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
    J Clin Oncol, 26(15): 2450-6. [Abstract] [Full-text]
84. IDMap: facilitating the detection of potential leads with therapeutic targets.
    Bioinformatics, 24(11): 1413-5. [Abstract] [Full-text]
85. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study.
    BJU Int, 101(12): 1519-23. [Abstract] [Full-text]
86. Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells.
    BMC Cancer, 8: 135. [Abstract] [Full-text]
87. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Mol Pharmacol, 73(6): 1632-42. [Abstract] [Full-text]
88. Identification of the xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 as a new target of cisplatin in breast cancer cells: molecular and cellular mechanisms of inhibition.
    Mol Pharmacol, 73(6): 1761-8. [Abstract] [Full-text]
89. Effect of artificial ascites on thermal injury to the diaphragm and stomach in radiofrequency ablation of the liver: experimental study with a porcine model.
    AJR Am J Roentgenol, 190(6): 1659-64. [Abstract] [Full-text]
90. Flexible porous metal-organic frameworks for a controlled drug delivery.
    J Am Chem Soc, 130(21): 6774-80. [Abstract] [Full-text]
91. Frequency of medication errors with intravenous acetylcysteine for acetaminophen overdose.
    Ann Pharmacother, 42(6): 766-70. [Abstract] [Full-text]
92. Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer.
    Oncogene, 27(23): 3313-28. [Abstract] [Full-text]
93. Preoperative gabapentin prevents intrathecal morphine-induced pruritus after orthopedic surgery.
    Anesth Analg, 106(6): 1868-72. [Abstract] [Full-text]
94. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Ann Thorac Surg, 85(6): 1930-6; discussion 1936-7. [Abstract] [Full-text]
95. Infective endocarditis prevention: update on 2007 guidelines.
    Am J Med, 121(6): 484-6. [Abstract] [Full-text]
96. Photodynamic therapy for predominantly hemorrhagic lesions in neovascular age-related macular degeneration.
    Am J Ophthalmol, 145(6): 1052-1057. [Abstract] [Full-text]
97. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
    Br J Cancer, 98(11): 1774-80. [Abstract] [Full-text]
98. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
    J Clin Oncol, 26(16): 2699-706. [Abstract] [Full-text]
99. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
    J Clin Oncol, 26(16): 2690-8. [Abstract] [Full-text]
100. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
     J Clin Oncol, 26(16): 2683-9. [Abstract] [Full-text]
101. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
     J Clin Oncol, 26(16): 2674-82. [Abstract] [Full-text]
102. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
     J Clin Oncol, 26(16): 2636-43. [Abstract] [Full-text]
103. Individualizing treatment of patients with myeloma in the era of novel agents.
     J Clin Oncol, 26(16): 2761-6. [Abstract] [Full-text]
104. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
     J Clin Oncol, 26(16): 2717-24. [Abstract] [Full-text]
105. Uptake of antiretroviral treatment among people living with HIV in London: ethnicity, gender and sexual orientation.
     Sex Transm Infect, 84(3): 176-8. [Abstract] [Full-text]
106. Unemployment as a risk factor for AIDS and death for HIV-infected patients in the era of highly active antiretroviral therapy.
     Sex Transm Infect, 84(3): 183-6. [Abstract] [Full-text]
107. Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso.
     Sex Transm Infect, 84(3): 167-70. [Abstract] [Full-text]
108. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.
     BMJ, 336(7655): 1227-31. [Abstract] [Full-text]

© 2004-2008 Chemotherapy Research Today. All Rights Reserved.